间充质干细胞通过免疫调节机制治疗炎症性肠病的研究进展

Advances in the study of mesenchymal stem cells for the treatment of inflammatory bowel disease by immunoregulation

炎症性肠病(inflammatory bowel disease, IBD)是一种病因尚不明确的,与自身免疫相关的慢性炎症性疾病。肠道黏膜免疫系统的异常是导致IBD发生发展的关键性因素。间充质干细胞(mesenchymal stem cell, MSC)是一类具有自我更新和多向分化潜能的细胞,这一特征使其被视为治疗多种疾病的重要方法。越来越多的研究者认为MSC的免疫调节功能对IBD的治疗至关重要,当组织受到损伤后,MSC通过调节免疫反应改善炎症微环境,在组织修复的过程中发挥重要作用。本文主要对MSC通过免疫调节机制治疗IBD的研究进展作一概述。

Inflammatory bowel disease(IBD) is an autoimmune chronic inflammatory disease of unknown etiology. An abnormality in the intestinal mucosal immune system is a major factor in the development of IBD. Mesenchymal stem cells(MSC) have a self-renewal capacity and multipotent differentiation potential, which makes them important for the treatment of various diseases. Increasingly more researchers believe that the immunomodulatory function of MSCs is essential for the treatment of IBD. Upon tissue injury, MSCs improve the inflammatory microenvironment by regulating the immune response, which plays an important role in the process of tissue repair. This article mainly summarizes the research progress of MSCs in the treatment of IBD through immunomodulatory mechanisms.